Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV

Bibliography

• Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update 2009. Available from: http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf. [Accessed 12th October 2010]
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1st December 2009. p. 1-161. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 12 October 2010]
   Google Scholar
• European AIDS Clinical Society. Clinical management and treatment of HIV infected adults in Europe (version 5-2). Available from: http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines_ FullVersion.pdf. [Accessed 12 October 2010]
   Google Scholar
• World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf [Accessed 12 October 2010]
   Google Scholar
• Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-13
   PubMedGoogle Scholar
• Abbott Laboratories. Abbott received U.S. FDA approval for heat-stable Norvir® (ritonavir) tablets. 11th February 2010. Available from: http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0820.htm [Accessed 12 October 2010]
   Google Scholar
• Tho I, Liepold B, Rosenberg J, Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur J Pharm Sci 2010;40:25-32
   PubMed Web of Science ®Google Scholar
• Ng J, Klein C, Causemaker C, A comparison of the single dose bioavailability of a ritonavir tablet formulation relative to the ritonavir soft gelatin capsule in healthy adult subjects [abstract TUPE0076]. 17th International AIDS Conference; 3 – 8 August 2008; Mexico City, Mexico. Poster available from: www.medadvocates.org/resources/conferences/international_aids_ conferences/17/lopinavir_index/17N.pdf
   Google Scholar
• Klein C, Chiu YL, Awni W, A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects [abstract THAB04]. 17th International AIDS Conference; 3 – 8 August 2008; Mexico City, Mexico
   Google Scholar
• Klein CE, Chiu YL, Awni W, The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects [abstractP247]. 7th International Congress on Drug Therapy in HIV Infection; 9 – 13 November 2008 Glasgow, Scotland, Poster available from: www.hivandhepatitis.com/2008icr/hiv9/docs/posters/KleinRTVtablet.pdf
   Google Scholar
• Abbott Laboratories, Norvir®, ritonavir tablets, oral solution prescribing information. North Chicago, IL; 2010
   Google Scholar
• Abbott Laboratories, Norvir ®, ritonavir capsules (soft gelatin) prescribing information. North Chicago, IL; 2010
   Google Scholar
• Klein CE, Chiu YL, Awni W, The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007;44:401-10
   PubMed Web of Science ®Google Scholar
• Gathe J, da Silva B, Loutfy M, Study M05-730 Primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir tablets once daily vs twice daily, co-administered with tenofovir DF + emtricitabine in ARV-naive HIV-1 infected subjects [abstract 775]. 15th Conference on Retroviruses and Opportunistic Infections (CROI). 3 – 6 February 2008. Boston, MA
   Google Scholar
• Schrader S, Chuck SK, Rahn LW, Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules. AIDS Res Ther 2008;5:21
   PubMedGoogle Scholar
• Ofotokun I, Chuck SK, Schmotzer B, O'Neil KL. Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients. AIDS Res Ther 2009;6:29
   PubMedGoogle Scholar
• Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-69
   PubMed Web of Science ®Google Scholar
• Barry M, Mulcahy F, Merry C, Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP, Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9
   PubMed Web of Science ®Google Scholar
• Elion R, Gathe J, Rashbaum B, The single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; “QUAD”) maintains a high rate of virologic suppression, and cobicistat is an effective pharmacoenhancer through 48 weeks [poster H-938B]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September 2010; Boston, MA
   Google Scholar
• German P, Warren D, West S, Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55(3):323-9
   PubMedGoogle Scholar
• Mathias A, Liu HC, Warren D, Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir [abstract 28]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7 – 9 April 2010; Sorrento, Italy
   Google Scholar
• Ramanatham S, Warren D, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir [poster A1-1301]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September, 2009 San Francisco, CA
   Google Scholar